Mandate

Vinge advises Cellink in directed new issues of shares of MSEK 946

Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.

The subscription price has been set through a so‑called accelerating book building procedure performed by Carnegie and J.P. Morgan and corresponds to a discount of 1.7% compared to the share’s closing date rate on Nasdaq Stockholm. Almost 4.3 million shares have been issued by virtue of the authorization resolved by the general meeting and approximately 1.6 million shares have been issued conditional upon approval by an extraordinary general meeting. The purpose of the new issues of shares is, in part, financing of the cash element of the purchase price for the acquisition of Scienion Ag., and, in part, to create scope for Cellink’s continued M&A agenda.

Vinge’s team primarily consisted of Anders StridEdin Agic and Victoria Gunnerek.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026